These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 16802322)
41. Vps35 Deficiency Impairs Cdk5/p35 Degradation and Promotes the Hyperphosphorylation of Tau Protein in Retinal Ganglion Cells. Gao L; Xiao H; Ai LQ; Chen C; Lin S; Zhou Y; Ye J; Liu W Invest Ophthalmol Vis Sci; 2020 Jan; 61(1):1. PubMed ID: 31995153 [TBL] [Abstract][Full Text] [Related]
42. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. Urushitani M; Nakamizo T; Inoue R; Sawada H; Kihara T; Honda K; Akaike A; Shimohama S J Neurosci Res; 2001 Mar; 63(5):377-87. PubMed ID: 11223912 [TBL] [Abstract][Full Text] [Related]
43. The Cdk5/p35 kinases modulate leptin-induced STAT3 signaling. He Y; Kastin AJ; Hsuchou H; Pan W J Mol Neurosci; 2009 Sep; 39(1-2):49-58. PubMed ID: 19156541 [TBL] [Abstract][Full Text] [Related]
44. The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins. Kanungo J; Zheng YL; Amin ND; Pant HC J Neurochem; 2008 Sep; 106(5):2236-48. PubMed ID: 18662245 [TBL] [Abstract][Full Text] [Related]
45. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. Bayer KU; LeBel E; McDonald GL; O'Leary H; Schulman H; De Koninck P J Neurosci; 2006 Jan; 26(4):1164-74. PubMed ID: 16436603 [TBL] [Abstract][Full Text] [Related]
46. Is persistent activity of calcium/calmodulin-dependent kinase required for the maintenance of LTP? Chen HX; Otmakhov N; Strack S; Colbran RJ; Lisman JE J Neurophysiol; 2001 Apr; 85(4):1368-76. PubMed ID: 11287461 [TBL] [Abstract][Full Text] [Related]
47. CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. Hou ST; Jiang SX; Aylsworth A; Ferguson G; Slinn J; Hu H; Leung T; Kappler J; Kaibuchi K J Neurochem; 2009 Nov; 111(3):870-81. PubMed ID: 19735446 [TBL] [Abstract][Full Text] [Related]
48. Role of cyclin-dependent kinase 5 and its activator P35 in local axon and growth cone stabilization. Hahn CM; Kleinholz H; Koester MP; Grieser S; Thelen K; Pollerberg GE Neuroscience; 2005; 134(2):449-65. PubMed ID: 15964697 [TBL] [Abstract][Full Text] [Related]
49. Memory consolidation induces N-methyl-D-aspartic acid-receptor- and Ca2+/calmodulin-dependent protein kinase II-dependent modifications in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor properties. Bevilaqua LR; Medina JH; Izquierdo I; Cammarota M Neuroscience; 2005; 136(2):397-403. PubMed ID: 16182449 [TBL] [Abstract][Full Text] [Related]
50. Activation of NMDA receptors induces protein kinase A-mediated phosphorylation and degradation of matrin 3. Blocking these effects prevents NMDA-induced neuronal death. Giordano G; Sánchez-Pérez AM; Montoliu C; Berezney R; Malyavantham K; Costa LG; Calvete JJ; Felipo V J Neurochem; 2005 Aug; 94(3):808-18. PubMed ID: 16000164 [TBL] [Abstract][Full Text] [Related]
51. Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5. Kobayashi H; Saito T; Sato K; Furusawa K; Hosokawa T; Tsutsumi K; Asada A; Kamada S; Ohshima T; Hisanaga S J Biol Chem; 2014 Jul; 289(28):19627-36. PubMed ID: 24872417 [TBL] [Abstract][Full Text] [Related]
52. p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide. Seyb KI; Ansar S; Li G; Bean J; Michaelis ML; Dobrowsky RT J Mol Neurosci; 2007; 31(1):23-35. PubMed ID: 17416967 [TBL] [Abstract][Full Text] [Related]
53. Interaction with the NMDA receptor locks CaMKII in an active conformation. Bayer KU; De Koninck P; Leonard AS; Hell JW; Schulman H Nature; 2001 Jun; 411(6839):801-5. PubMed ID: 11459059 [TBL] [Abstract][Full Text] [Related]
55. Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. Moriguchi S; Shioda N; Han F; Yeh JZ; Narahashi T; Fukunaga K Hippocampus; 2009 Sep; 19(9):844-54. PubMed ID: 19253410 [TBL] [Abstract][Full Text] [Related]
56. Regulation of Sox6 by cyclin dependent kinase 5 in brain. Rudrabhatla P; Utreras E; Jaffe H; Kulkarni AB PLoS One; 2014; 9(3):e89310. PubMed ID: 24662752 [TBL] [Abstract][Full Text] [Related]
57. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. Cho DH; Lee EJ; Kwon KJ; Shin CY; Song KH; Park JH; Jo I; Han SH J Neurochem; 2013 Sep; 126(5):685-95. PubMed ID: 23581463 [TBL] [Abstract][Full Text] [Related]
58. Cyclin-dependent kinase 5 modulates the P2X2a receptor channel gating through phosphorylation of C-terminal threonine 372. Coddou C; Sandoval R; Castro P; Lazcano P; Hevia MJ; Rokic M; Hall B; Terse A; Gonzalez-Billault C; Kulkarni AB; Stojilkovic SS; Utreras E Pain; 2017 Nov; 158(11):2155-2168. PubMed ID: 28809765 [TBL] [Abstract][Full Text] [Related]